Gen Ilac

Sidmak Laboratories, Inc., Announces Alliance with GEN ILAC for Distribution in Turkey of Cyclosporine Soft Gelatin Capsules and Oral Solution, USP [MODIFIED]Sidmak Laboratories, Inc.

Sidmak Laboratories, Inc., Announces Alliance with GEN ILAC for Distribution in Turkey of Cyclosporine Soft Gelatin Capsules and Oral Solution, USP [MODIFIED]

East Hanover, NJ: June 2002 - Sidmak Laboratories, Inc., has announced a distribution arrangement with GEN ILAC (Pharmaceuticals) Ltd. in Turkey for the Sidmak generic product, Cyclosporine Soft Gelatin Capsules, USP [MODIFIED] in 25 and 100-mg strength and Cyclosporine Oral Solution, USP [MODIFIED].

Cyclosporine from Sidmak Laboratories - indicated for immunosuppresant therapy in transplant patients - is FDA-approved and AB-rated bioequivalent to Neoral® Soft Gelatin Capsules (Cyclosporine capsules, USP [MODIFIED]) and Oral Solution, and is completely substitutable for and therapeutically interchangeable, dose for dose, with Neoral.

Mr. John Kober, Vice President of Business Development and Strategic Planning with Sidmak, stated, "This distribution arrangement with GEN ILAC fits into our long-term strategy of expanding our global reach through marketing and distribution alliances.
...
GEN ILAC will be our representative in Turkey and the Turkish Republic of Northern Cyprus.Sidmak will supply Cyclosporine and work with GEN ILAC on the Health Registration in Turkey.GEN ILAC will handle the sales, marketing, and distribution of the product.GEN ILAC has excellent capabilities and will make a terrific partner with Sidmak."

GEN ILAC offers Sidmak access to a population of over 67 million in Turkey, with more than 1500 hospitals in the country.GEN ILAC excels in the marketing of both niche and high-profile Pharmaceuticals.

For more information about GEN ILAC or Cyclosporine, contact Sidmak at at 1-973-386-5566 or 1-800-922-0547, or visit our website at http://www.cyclosporinesidmak.com/

Cyclosporine Soft Gelatin Capsules and Oral Solution, USP [MODIFIED] should be used only by physicians experienced with this therapeutic class and this product.Cyclosporine [MODIFIED], an immunosuppressant, may increase the susceptibility to infection and the development of neoplasia.When used with other immunosuppressive agents in transplant patients, increased susceptibility to infection and the possible development of lymphoma and other neoplasms may result from the increase in the degree of immunosuppression.

Cyclosporine Soft Gelatin Capsules and Oral Solution USP [MODIFIED] have increased bioavailability in comparison with Sandimmune®* Soft Gelatin Capsules and Oral Solution (cyclosporine capsules and oral solution, USP [NON-MODIFIED]), are not bioequivalent, and cannot be used interchangeably without physician supervision.Cyclosporine [MODIFIED] blood concentrations should be monitored to avoid toxicity due to high concentrations.